Bayer's Weinand On Broadening Value-Based Pricing Views
Executive Summary
Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.
You may also be interested in...
US Outcomes-Based Contracts In Oncology? CAR-T Could Be Case Study
Groundbreaking but potentially very expensive new CAR-T treatments for cancer could be suited to outcomes-based contracts, Harvard Pilgrim's Sherman suggests.
Bayer Bets On Oncology Pipeline, Vows To Increase 2017 R&D Budget
Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.